PURPLE BIOTECHPP

PURPLE BIOTECH

4.1ILAD
0.00.00%
At close at 14:24 GMT
ILA
No trades
See on Supercharts

PPBT fundamentals

Key facts

Market capitalization‪22.79 M‬ILS
Basic EPS (TTM)−0.05ILS
Founded1968
CEOGil Efron
About

Purple Biotech Ltd. is a clinical-stage company, which engages in developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The oncology pipeline includes CM24, NT219, and CAPTN-3. The CM24 is a humanized monoclonal antibody that blocks CEACAM1, which supports tumor immune evasion and survival through multiple pathways. The NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. The CAPTN-3, a preclinical platform of conditionally activated tri-specific antibodies, which engage both T cells and NK cells to induce a strong, localized immune response within the tumor microenvironment. The company was founded by John Paul Waymack on August 12, 1968 and is headquartered in Rehovot, Israel.

Ownership
‪‪555.90 M‬‬
Free Float shares
‪‪544.77 M‬‬ (98%)
Closely held shares
‪‪11.13 M‬‬ (2%)
Free Float shares
‪‪544.77 M‬‬ (98%)
Closely held shares
‪‪11.13 M‬‬ (2%)
Capital structure
Market cap
‪‪22.79 M‬‬
Debt
‪‪510.59 K‬‬
Minority interest
‪‪178.89 K‬‬
Cash & equivalents
‪‪26.41 M‬‬
Enterprise value
‪‪−2.93 M‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪22.79 M‬‬
Price to earning ratio (P/E)
Price to sales ratio (P/S)
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
Price to sales ratio (P/S)
Valuation ratios
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25

Growth and Profitability

Company’s recent performance and margins

Performance
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪‪−16.00 M‬‬
‪‪−12.00 M‬‬
‪‪−8.00 M‬‬
‪‪−4.00 M‬‬
‪0.00‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−5.20 M‬‬
‪‪−3.90 M‬‬
‪‪−2.60 M‬‬
‪‪−1.30 M‬‬
‪0.00‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−1.80 M‬‬
‪‪−1.35 M‬‬
‪‪−900.00 K‬‬
‪‪−450.00 K‬‬
‪0.00‬

Dividends

Dividend yield, history and sustainability

No dividends
PPBT has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company

Debt level and coverage
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪‪−20.00 M‬‬
‪0.00‬
‪‪20.00 M‬‬
‪‪40.00 M‬‬
‪‪60.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪30.00 M‬‬
‪‪60.00 M‬‬
‪‪90.00 M‬‬
‪‪120.00 M‬‬
Assets
Liabilities